Caribou Biosciences (NASDAQ:CRBU) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Caribou Biosciences (NASDAQ:CRBU) in a research note issued to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $9.00 price target on the stock.

Separately, Royal Bank of Canada restated an “outperform” rating and issued a $14.00 target price on shares of Caribou Biosciences in a research note on Wednesday, August 7th.

Caribou Biosciences Stock Down 4.8 %

NASDAQ CRBU traded down $0.10 on Friday, reaching $1.99. The company had a trading volume of 1,725,808 shares, compared to its average volume of 1,717,996. The company’s fifty day moving average is $2.04 and its 200 day moving average is $2.24. Caribou Biosciences has a 52-week low of $1.50 and a 52-week high of $8.33. The stock has a market capitalization of $180.20 million, a P/E ratio of -1.21 and a beta of 2.26.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The company had revenue of $2.02 million during the quarter, compared to the consensus estimate of $3.37 million. On average, research analysts expect that Caribou Biosciences will post -1.67 EPS for the current year.

Institutional Trading of Caribou Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. PFM Health Sciences LP grew its position in shares of Caribou Biosciences by 5.5% during the 3rd quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after acquiring an additional 223,299 shares during the period. Vanguard Group Inc. grew its holdings in Caribou Biosciences by 3.8% during the first quarter. Vanguard Group Inc. now owns 4,110,795 shares of the company’s stock valued at $21,129,000 after purchasing an additional 148,751 shares during the period. Dimensional Fund Advisors LP increased its position in Caribou Biosciences by 25.7% in the second quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock worth $4,302,000 after buying an additional 536,162 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Caribou Biosciences by 6.5% during the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after buying an additional 124,782 shares during the last quarter. Finally, FMR LLC lifted its position in shares of Caribou Biosciences by 7.4% during the 3rd quarter. FMR LLC now owns 1,581,493 shares of the company’s stock valued at $3,100,000 after buying an additional 109,606 shares during the last quarter. Institutional investors own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.